GF003AF
Fibroblast Growth Factor basic, human recombinant, animal-free
The Fibroblast Growth Factor-basic (or bFGF protein) is a heparin binding growth factor which stimulates the proliferation of a wide variety of cells including mesenchymal, neuroectodermal & endothelial cells.
Synonym(s):
FGF-2, bFGF, basic-FGF, Heparin-Binding Growth Factor 2, Prostatropin
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352202
eCl@ss:
32160405
NACRES:
NA.75
Recommended Products
biological source
human
Quality Level
Assay
>95% (SDS-PAGE)
manufacturer/tradename
Chemicon®
technique(s)
cell culture | stem cell: suitable
impurities
<0.1 EU/μg Endotoxin (of bFGF)
input
sample type epithelial cells
sample type mesenchymal stem cell(s)
sample type: human embryonic stem cell(s)
sample type neural stem cell(s)
sample type pancreatic stem cell(s)
NCBI accession no.
UniProt accession no.
General description
Fibroblast Growth Factor-basic (bFGF) is a heparin binding growth factor which stimulates the proliferation of a wide variety of cells including mesenchymal, neuroectodermal and endothelial cells. bFGF also exerts a potent angiogenic activity in vivo. Human bFGF is a 17.2 kDa protein containing 155 amino acid residues. Xu, et al. demonstrated that bFGF synergizes with the BMP antagonist noggin to sustain undifferentiated proliferation of human embryonic stem (hES) cells under feeder-free conditions. GF003AF was developed without animal-based ingredients and can be used for the culture of hES cells in a feeder-free, animal-free culture system.
Product Source: expressed in E. coli
Application
For most in vitro applications, bFGF exerts its biological activity in the concentration range of 0.1 to 10.0 ng/mL. Responding cells are (partial list): Endothelial, mesenchymal cells. Human ES cells require concentrations in the range of 4 to 100 ng/ml, depending on the method of culture
Physical form
Lyophilized from a solution of 5mM Tris, pH 7.6 with 150 mM NaCl.
Storage and Stability
Maintain the lyophilized material at -20°C until expiration date as stated on the label.
General applications:
After a quick spin, reconstitute in 0.1M phosphate buffer, pH 6.8, to a concentration of 0.1-1.0 mg/mL. Reconstituted bFGF should be stored in working aliquots at -20°C for up to six months. Multiple freeze/thaw cycles will result in significant loss of activity.
For Human ES cell culture:
After a quick spin, reconstitute to 10 μg/mL in a filtered solution of 0.5% BSA, 1 mM DTT, and 10% glycerol in Dulbecco′s PBS. Aliquot and store at -20°C for up to six months. This solution can then thawed and diluted to 4 ng/mL for the culture of human ES cells with a feeder layer, or to 8 ng/mL to supplement mouse embryonic fibroblast-conditioned medium (for feeder-free human ES cell culture).
General applications:
After a quick spin, reconstitute in 0.1M phosphate buffer, pH 6.8, to a concentration of 0.1-1.0 mg/mL. Reconstituted bFGF should be stored in working aliquots at -20°C for up to six months. Multiple freeze/thaw cycles will result in significant loss of activity.
For Human ES cell culture:
After a quick spin, reconstitute to 10 μg/mL in a filtered solution of 0.5% BSA, 1 mM DTT, and 10% glycerol in Dulbecco′s PBS. Aliquot and store at -20°C for up to six months. This solution can then thawed and diluted to 4 ng/mL for the culture of human ES cells with a feeder layer, or to 8 ng/mL to supplement mouse embryonic fibroblast-conditioned medium (for feeder-free human ES cell culture).
Analysis Note
Specific Activity: Human FGF-b is fully biologically active when compared to standards. The ED50 was determined by the dose-dependent stimulation of thymidine uptake by NIH3T3 cells expressing FGF receptors.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Hai Jin et al.
Journal of controlled release : official journal of the Controlled Release Society, 338, 773-783 (2021-09-17)
Pro-angiogenic growth factors have been studied as potential therapeutics for cardiovascular diseases like critical limb ischemia (CLI). However, the translation of these factors has remained a challenge, in part, due to problems associated with safe and effective delivery. Here, we
Leidan Huang et al.
Acta biomaterialia, 129, 73-83 (2021-05-09)
Vascularization is a critical step following implantation of an engineered tissue construct in order to maintain its viability. The ability to spatially pattern or direct vascularization could be therapeutically beneficial for anastomosis and vessel in-growth. However, acellular and cell-based strategies
Mitra Aliabouzar et al.
Ultrasonics sonochemistry, 66, 105109-105109 (2020-04-06)
An ultrasound standing wave field (SWF) has been utilized in many biomedical applications. Here, we demonstrate how a SWF can enhance drug release using acoustic droplet vaporization (ADV) in an acoustically-responsive scaffold (ARS). ARSs are composite fibrin hydrogels containing payload-carrying
Sarah E Elzinga et al.
Frontiers in immunology, 13, 1012594-1012594 (2022-10-18)
Obesity, prediabetes, and diabetes are growing in prevalence worldwide. These metabolic disorders are associated with neurodegenerative diseases, particularly Alzheimer's disease and Alzheimer's disease related dementias. Innate inflammatory signaling plays a critical role in this association, potentially via the early activation
Leiming Xia et al.
Cancer cell international, 21(1), 337-337 (2021-07-05)
Additional epidermal growth factor receptor (EGFR) mutations confer the drug resistance to generations of EGFR targeted tyrosine kinase inhibitor (EGFR-TKI), posing a major challenge to developing effective treatment of lung adenocarcinoma (LUAD). The strategy of combining EGFR-TKI with other synergistic
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service